FDA Panel Clears 6 of 7 Banned Peptides for Compounding, Sparking Safety Debate

An FDA Pharmacy Compounding Advisory Committee voted to remove six peptides from the Category 2 ban list (BPC-157, KPV, TB-500, MOTs-C, epitalon, semax) while keeping emideltide restricted, signaling broader access to unapproved peptides via compounding despite limited safety and efficacy data; the non-binding recommendations come amid RFK Jr.’s push to expand peptide use, raising questions about real-world safety and effectiveness.